[1] 杨晨,朱帆东,夏阳,等.MRI多模态影像组学鉴别肝细胞肝癌与肝富血供良性病变的应用价值[J].放射学实践,2023,38(5):581-586. [2] 邢飞,朱文静,姜吉锋,等.肝细胞癌伴“结中结”的肝胆期影像表现分型及其病理学特征[J].中华肝脏病杂志,2024,32(11):989-996. [3] Guo D Z, Zhang X, Zhang S Q, et al. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts[J].Mol Cancer, 2024, 23(1): 157. [4] Kacała A, Dorochowicz M, Matus I, et al. Hepatic hemangioma: review of imaging and therapeutic strategies[J].Medicina (Kaunas), 2024, 60(3): 449. [5] Bo Z, Song J, He Q, et al. Application of artificial intelligence radiomics in the diagnosis, treatment,and prognosis of hepatocellular carcinoma[J]. Comput Biol Med,2024, 173(5):108337. [6] Huang M, Song C, Zhou X, et al. Tissue-matched analysis of MRI evaluating the tumor infiltrating lymphocytes in hepatocellular carcinoma[J]. Int J Cancer, 2025, 156(8): 1634-1643. [7] Joanna G C, Marcin S, Agata K, et al. The role of alpha-fetoprotein (AFP) in contemporary oncology: the path from a diagnostic biomarker to an anticancer drug[J]. Int J Mol Sci, 2023, 24(3): 2539. [8] Takayama I Y, Kanetaka K, Kobayashi S, et al. High serum alpha-fetoprotein and positive immunohistochemistry of alpha-fetoprotein are related to poor prognosis of gastric cancer with liver metastasis[J]. Sci Rep, 2024, 14(1): 3695. [9] Xu X, Peng Q, Jiang X, et al. Altered glycosylation in cancer: molecular functions and therapeutic potential[J]. Cancer Commun (Lond), 2024, 44(11): 1316-1336. [10] Lu Y, Lin B, Li M.The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma[J]. Front Oncol, 2024, 14(1): 1363695. [11] 李瑞峰,郭秋峰,袁明.原发性肝癌MRI肿瘤影像学表现与血管新生的关联性及预后影响因素分析[J].中国CT和MRI杂志,2024,22(5):116-1197. [12] 邓丹,邱世香,赵茂林,等.兔VX2肝癌移植瘤模型的建立及其影像学评估[J].西部医学,2022,34(7):979-984. [13] 杨孺牛,符进,王德琴.多模态影像技术联合超声剪切波弹性成像对代谢相关性脂肪性肝病的诊断价值[J].肝脏,2023,28(9):1101-1104. [14] 施莹,柏根基,孙阳.多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨[J].实用肝脏病杂志,2022,25(5):722-725. [15] 姚致远,赵文超,张恭,等.基于增强磁共振成像影像组学的肝细胞癌靶向联合免疫治疗疗效预测研究[J].解放军医学院学报,2024,45(8):817-823. [16] Chen J, Kaya N A, Zhang Y, et al. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ′bad apple′ effect on clinical trajectory[J]. J Hepatol,2024, 81(4): 667-678. [17] Bercu A, Dufouil C, Debette S, et al. Prediction of dementia risk from multimodal repeated measures: the added value of brain MRI biomarkers[J]. Alzheimers Dement (Amst),2024, 25(2): e12578. [18] He C, Hu Z, Lin Z,, et al. Chitinase-3 like-protein-1,a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis[J]. BMC Cancer, 2024, 24(1): 1042. [19] Xu Y, Sun F, Tian Y, et al. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma[J]. Int Immunopharmacol, 2024, 129(5): 111628. [20] Chen L, Song S, Chen M, et al. Serum pentraxin-3 as a potential biomarker for diagnosis and prognosis in primary liver cancer: an observational study[J]. Medicine (Baltimore),2024, 103(50): e40421. |